Javascript er ikke aktivert i din nettleser. Dette er nødvendig for å bruke Oncolex. Kontakt din systemadministrator for å aktivere JavaScript.

Referanser til kreft i bukspyttkjertel

  1. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av pasienter med pacreaskreft. IS-2094 Helsedirektoratet 01-2014 
  2. Cancer in Norway 2015, Cancer Registry of Norway, Institute of Population-based Research. Oslo, Norway
  3. Sobin LH, Gospodarowic M, Wettekind C, red. TNM: classification of malignant tumors. 7 utg. Oxford: Willey-BackwII; 2010
  4. Verbeke CS, Gladhaug IP. Resection margin involvement and tumour origin in pancreatic head cancer. Br J Surg 2012;99(8):1036-49
  5. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet 2011;378(9791):607-20
  6. Ghaneh P, Castello E, Neoptolemos JP. Biology and management of pancreatic cancer. Gut 2007;56(8):1134–52
  7. Costello E, Neoptolemos JP. Pancreatic cancer in 2010: new insights for early intervention and detection. Nat Rev Gastroenterol Hepatol 2011;8(2):71-3
  8. Warshaw AL, Lillemoe KD, Fernandez-Del Castillo C. Pancreatic surgery for adenocarcinoma. Curr Opin Gastroenterol 2012;28(5):488-93
  9. Westgaard A, Tafjord S, Farstad IN, Cvancorva M, Eide TJ, Mathisen Ø, et al. Resectable adenocarcinomas in the pancreatic head: the retroperitoneal resection margin is an independent prognostic factor. BMC Cancer 2008;8:5
  10. Westgaard A, Larønningen S, Mellem C, Eide TJ, Clausen OPF, Møller B, et al. Are survival predictions reliable? Hospital volume versus standardisation of histopathological reporting for accuracy of survival estimates after pancreatoduodenectomy for adenocarcinoma. Eur J Cancer 2009, doi: 10.1016/j.ejca.2009.03.019
  11. Carpelan-Helström M, Nordling S, Pukkala E, Sankila R, Lüttges J, Klöppel G, et al. Does anyone survive pancreatic ductal adenocarcinoma? A nationwide study re-evaluating the data of the Finnish Cancer Registry. Gut 2005; 54: 385–387
  12. Michl P, Gress TM. Current concepts and novel targets in advanced pancreatic cancer. Gut 2013;62(2):317-26

Prosedyrer i Oncolex kan ikke erstatte faglig veiledning fra kvalifisert veileder. Den som følger prosedyrene har et selvstendig ansvar for at det foreligger nødvendig godkjenning, lisens eller autorisasjon.
Oslo universitetssykehus HF © 2016